Syntara (SNT) H2 2025 earnings summary

Executive summary

• Focus shifted to clinical-stage drug development, primarily targeting extracellular matrix dysfunction in blood cancers and fibrotic diseases, following the sale of the mannitol respiratory business unit in October 2023.

• Lead candidate amsulostat (SNT-5505) advanced in myelofibrosis and myelodysplastic syndrome, with Fast Track and Orphan Drug Designations from the FDA.

• Multiple capital raisings in July and December 2024 secured $20 million to fund clinical programs.

• Significant progress in clinical trials, including positive interim results for amsulostat in combination with ruxolitinib for myelofibrosis.

Financial highlights

• Net loss after tax for FY25 was $7.9 million, compared to a $15.1 million loss in FY24.

• Total current assets increased to $21.1 million, with $15.1 million in cash and cash equivalents at year-end.

• Total liabilities decreased to $5.4 million from $5.7 million.

• Profit from discontinued operations (mannitol business) was $4.3 million, including a $3.8 million bad debt write-back.

• Research and development tax incentive income of $5.6 million accrued.

Outlook and guidance

• Continued focus on advancing amsulostat through pivotal trials in myelofibrosis and MDS, with further FDA guidance shaping clinical development.

• Results from ongoing and new clinical trials expected in CYH1 2026.

• Ongoing pursuit of global and regional partnerships for late-stage development and commercialization.